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networkAbstract Gut microbiota of higher vertebrates is host-speciﬁc. The number and diversity of the
organisms residing within the gut ecosystem are deﬁned by physiological and environmental factors,
such as host genotype, habitat, and diet. Recently, culture-independent sequencing techniques have
added a new dimension to the study of gut microbiota and the challenge to analyze the large volume
of sequencing data is increasingly addressed by the development of novel computational tools and
methods. Interestingly, gut microbiota maintains a constant relative abundance at operational tax-
onomic unit (OTU) levels and altered bacterial abundance has been associated with complex diseases
such as symptomatic atherosclerosis, type 2 diabetes, obesity, and colorectal cancer. Therefore, the
study of gut microbial population has emerged as an important ﬁeld of research in order to ulti-
mately achieve better health. In addition, there is a spontaneous, non-linear, and dynamic interac-
tion among different bacterial species residing in the gut. Thus, predicting the inﬂuence of perturbed
microbe–microbe interaction network on health can aid in developing novel therapeutics. Here, we
summarize the population abundance of gut microbiota and its variation in different clinical states,
computational tools available to analyze the pyrosequencing data, and gut microbe–microbe inter-
action networks.Introduction
Metagenomics is the study of genetic material retrieved
directly from environmental samples including the gut, soil,
and water. Typically, human gut microbiota behaves like amulticellular organ, which consists of nearly 200 prevalent bac-
terial species and approximately 1000 uncommon species [1].
Several factors, such as diet and genetic background of the
host and immune status, affect the composition of the micro-
biota [2,3]. It is also shown that early environmental exposure
and the maternal inoculums have a large impact on gut micro-
biota in adulthood [4]. Gut microbiota complements the biol-
ogy of an organism in ways that are mutually beneﬁcial [5].
Gut microbiota can be studied using different approaches.
For instance, descriptive metagenomics can reveal community
structure and variation of the microbiome and microbial rela-
tive abundance is estimated based on different physiologicalnces and
Box 1 Glossary
Microbiome: the ecological community of commensal, symbiotic,
and pathogenic microorganisms that literally share our body space.
Metagenome: all the genetic material present in an environmental
sample, consisting of the genomes of many individual organisms.
Metagenomic sequencing: the high-throughput sequencing of
metagenome using next-generation sequencing technology.
Metagenomics: the study of genetic material or the variation of
species recovered directly from environmental samples.
Descriptive metagenomics: estimation of microbial relative
abundance based on diﬀerent physiological and environmental
conditions to reveal community structure and variation of the
microbiome.
Functional metagenomics: the study of host–microbe and
microbe–microbe interactions toward a predictive dynamic
ecosystem model to reﬂect a connection between the identity of
a microbe or a community.
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tional metagenomics is the study of host–microbe and
microbe–microbe interactions toward a predictive, dynamic
ecosystem model. Such studies reﬂect connections between
the identity of a microbe or a community and their respective
functions in the environment (terms are deﬁned in Box 1) [8,9].
However, a major challenge in the study of gut microbiota is
the inability to culture most of the gut microbial species [10].
Several efforts have been previously made in this regard.
Gordon et al. identiﬁed 86 culturable species in human colonic
microbiota from three healthy adults (http://www.genome.
gov/Pages/Research/Sequencing/SeqProposals/HGMISeq.
pdf). Gut ecosystems are currently being studied in the native
state using 16S rRNA gene amplicon sequencing or whole
genome sequencing (WGS) techniques [11]. 16S rRNA gene
sequencing is widely used for phylogenetic reconstruction,
nucleic acid-based detection, and quantiﬁcation of microbial
diversity. In contrast, WGS additionally explores the functions
of the metagenome. The gut microbial community structure
and function have been studied in different host species,
including mouse [12], human [13], canine, [14], feline [14],
cow [15], and yak [15]. Despite inter-species differences in com-
munity structure and function, gut microbiota frequently play
a beneﬁcial role in host metabolism and immunity across
different species [16].
Large numbers of metagenomic sequence datasets have
been generated, thanks to the advances in WGS and 16S
rRNA pyrosequencing techniques [17]. These datasets are
available in different repositories including the National
Center for Biotechnology Information (NCBI) Sequence
Read Archive (SRA) (http://www.ncbi.nlm.nih.gov/sra), the
Data Analysis and Coordination Center (DACC) under the
Human Microbiome Project (HMP) (http://hmpdacc.org) sup-
ported by the National Institutes of Health (NIH), metage-
nomic data resource from the European Bioinformatics
Institute (EBI) (https://www.ebi.ac.uk/metagenomics/) and
the UniProt Metagenomic and Environmental Sequences
(UniMES) database (http://www.uniprot.org/help/unimes).
All these sequence archives also provide different tools for
the analysis of metagenomic sequences. Starting with the
ﬁrst-generation Sanger (e.g., Applied Biosystems) platforms
to the second-generation 454 Life Sciences Roche (e.g., GS
FLX Titanium) and Illumina (e.g., GA II, MiSeq, and
HiSeq) platforms and ﬁnally, the recently developed Ion
Torrent Personal Genome Machines (PGM) and Single-
Molecule Real-Time (SMRT) third generation sequencing
techniques introduced by Paciﬁc Bioscience have evolved
according to the need for generating cost-effective and faster
metagenomic sequencing techniques. The Roche-454
Titanium platform generates consistently longer reads com-
pared to the latest PGM platform. Whereas the MiSeq plat-
form from Illumina produces consistently higher sequence
coverage in both depth and breadth, the Ion Torrent is unique
for its speed of sequencing. However, the short read length,
higher complexity, and inherent incompleteness make metage-
nomic sequences difﬁcult to assemble and annotate [18]. The
sequences obtained from metagenomic studies are fragmented
(lies between 20 and 700 base pairs) and incomplete, because of
the limitations in the available sequencing techniques. Each
genomic fragment is sequenced from a single species, but
within a sample there are many different species, and for most
of them, a full genome is absent. It becomes impossible todetermine the species of origin of a particular sequence.
Moreover, the volume of sequence data acquired by environ-
mental sequencing is several orders of magnitude higher than
that acquired by sequencing of a single genome [19].It is well established that gut microbes constantly interact
among themselves and with the host tissues. Different types
of interactions are present, but most are of commensal nature.
The composition of the microbial community varies signiﬁ-
cantly between and within the host species. For example, there
is similarity of the microbiota between humans and mice at the
super kingdom level, but signiﬁcant difference exists at the
phylum level [20]. In this review, we focus on different gut
microbial communities residing within various host species,
different software used for metagenomic data analysis, clinical
importance of metagenomic studies, and importance of the
microbial network toward predicting ecosystem structure and
relationship among different species.Gut microbiota studied in mammals
The gut microbial composition of only a few host species has
been investigated with respect to diet, genetic potential, and
disease conditions (Table 1). It was reported that human gut
microbial communities were transplanted into gnotobiotic ani-
mal models, such as germ-free C57BL/6J mice, to examine the
effects of diet on the human gut microbiome [3,21]. Diet plays
a vital role in determining the composition of the resident gut
microbes [3]. Turnbaugh et al. found that the human gut
microbiome is shared among family members, who have simi-
lar microbiota even if they live at different locations [4]. In a
study, Tap et al. identiﬁed 66 dominant and prevalent opera-
tional taxonomic units (OTUs) from human fecal samples,
which included members of the genera Faecalibacterium,
Ruminococcus, Eubacterium, Dorea, Bacteroides, Alistipes,
and Biﬁdobacterium [22]. Another study in mice showed that
host genetics along with diet is important in shaping the gut
microbiota [23]. Using 16S rRNA sequencing, common
microbes that belong to the Cytophaga-Flavobacterium-
Bacteroides (CFB) phylum had been identiﬁed in the intestines
of mice, rats, and humans [24]. Diversity in the fecal bacterial
Table 1 Gut microbiota studies in different species using pyrosequencing technology
Host Sample source Sequencing method Amount of data retrieved GenBank ID Ref.
Mouse Cecum 16S rRNA-based sequencing 5088 16S rRNA sequences DQ014552DQ015671;
AY989911AY993908
[20]
Mouse Cecum and feces 16S rRNA-based sequencing 2878 16S rRNA sequences GQ491120GQ493997 [3]
Mouse Feces 16S rRNA-based sequencing 4172 16S rRNA sequences FJ032696FJ036849 ;
EU584214EU584231
[23]
Mouse and
zebraﬁsh
Zebraﬁsh intestine
and mouse cecum
16S rRNA-based sequencing 5545 16S rRNA sequences DQ813844DQ819377 [35]
Human Colonic mucosa and
feces
16S rRNA-based sequencing 11,831 16S rRNA sequences AY916135AY916390;
AY974810AY986384
[13]
Human Feces 16S rRNA-based sequencing 9773 16S rRNA sequences FJ362604FJ372382 [4]
Human Feces 16S rRNA-based sequencing 2064 16S rRNA sequences DQ325545DQ327606 [36]
Cat Feces 454 pyrosequencing 187,396 reads SRA012231.1 [37]
Dog Feces 454 pyrosequencing 201,642 reads SRA012231.1 [37]
Cow Rumen Whole genome sequencing 268 G of metagenomic DNA HQ706005HQ706094;
SRA023560
[38]
Yak Rumen 454 pyrosequencing 88 Mb genomic DNA NA [15]
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and feline gut samples [25]. The most abundant phyla in canine
gut microbiota were found to be Firmicutes, followed by
Actinobacteria and Bacteroidetes, whereas the most common
orders were Clostridiales, Erysipelotrichales, Lactobacillales
(Firmicutes), and Coriobacteriales (Actinobacteria). In rumi-
nants, the common rumen microbes are Fibrobacter succino-
genes, Ruminococcus albus, Ruminococcus ﬂavefaciens,
Butyrivibrio ﬁbrisolvens, and Prevotella [26].Gut metagenomics and disease: implications, scopes
and limitations
Commensal microbiota of the intestine play a key role in nor-
mal anatomical development and physiological function of
the human intestine as well as other organs or systems, such
as the brain [27] and the metabolic [28] and immune systems
[29]. Gut microbiota exerts a major impact on an organism’s
health by providing essential nutrients like vitamins and short
chain fatty acids, digesting complex polysaccharides, harvest-
ing energy and metabolizing drugs and environmental toxins
[30–34]. Although microbiota composition is relatively stable
in the adult, permanent changes in terms of diversity of the
community and/or abundance of individual phylotypes (dys-
biosis) may occur due to dietary and environmental alter-
ations and genetic mutation of the host [30,31]. This has
been associated with the development of various diseases
related to the digestive system, such as inﬂammatory bowel
disease (IBD) [39,40], irritable bowel syndrome (IBS) [41],
and non-alcoholic hepatitis; obesity and obesity-related meta-
bolic diseases like atherosclerosis [42] and type 2 diabetes
(T2D); neurological disorders like Alzheimer’s disease [43–
45]; atopy and asthma [46]; and cancer [47,48]. The number
of publications in PubMed could reﬂect the importance of
gut microbiota in different diseases to some extent. As shown
in Figure 1, association of gut microbiota is highest with obe-
sity followed by cancer. Bacterial species that were reported
with increased abundance under certain disease conditions
are mentioned in Table 2. It is interesting to note that in dif-
ferent disease conditions, distinct types of bacterial species
become abundant.It is critical to deﬁne healthy microbiota and the deviations
related to etiopathogenesis of diseases. This would allow us to
predict the development and/or progression of diseases and fos-
ter the idea of microbiota-targeted therapy. Metagenomic
sequencing has revealed that bacteria constitute the over-
whelming majority of gut microbiota in health and there is
remarkable inter-individual conservation at the phylum level.
For example, in more than 90% of healthy individuals, gut bac-
teria belong to two major phyla, Bacteroides and Firmicutes
[54]. However, efforts to deﬁne a core microbiome resulted in
mixed outcomes. Qin et al. analyzed 3.3 million non-
redundant microbial genes from intestinal samples of 124
Europeans [55]. They found that 18 species were present in all
individuals, while 57 and 75 species were detected in >75%
and >50% of the population, respectively [55]. In contrast,
Turnbaugh et al. reported that a functional core microbiome
exists in human gut [4], since gut microbiota serves critical
metabolic and immunological functions to maintain homeosta-
sis. In fact, studies with discrete population groups have indi-
cated that the super-kingdom level conservation rapidly
disappears lower in the phylogenetic hierarchy, giving rise to
a ‘‘microbiota ﬁngerprint’’ of an individual at the levels of
genus, species, and strain. This is underscored by the sharing
of only approximately 40% species by monozygotic twins
[12]. Interestingly, the individual gut microbiota is more unique
under healthy conditions than during disease, when the diver-
sity generally decreases. It is believed that the ratio of poten-
tially pathogenic to beneﬁcial commensal microbes, rather
than the presence of a speciﬁc organism or a group, is more cru-
cial for disease development [56]. However, a single pathobiont
(commensal turned into a pathogen) has also been reported to
cause disease under speciﬁc genetic and environmental condi-
tions. Bloom et al. demonstrated that commensal Bacteroides
isolates induce disease in genetically-modiﬁed (il10r2/ with
dominant-negative TGF-betaR2 expression in T cells) IBD-
susceptible mice, but not in IBD-nonsusceptible mice [57].
Importantly, metagenomic sequencing has unearthed a sep-
arate kingdom of resident viral species, many of which were
unknown so far, constituting the ‘‘gut virome’’ [58]. Reyes
et al. sequenced the viromes isolated from fecal samples of
monozygotic twins and their mothers, and compared them
with the total fecal DNA. This experiment revealed that the
Figure 1 Association of gut microbiota with disease in PubMed publications
PubMed publications on different diseases involving gut microbiota were searched on February 09, 2015. IBD, inﬂammatory bowel
disease; T2D, type 2 diabetes; CD, Crohn’s disease.
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highly similar, whereas individual viromes were unique despite
their genetic similarity. They also performed a longitudinal
study for one year on the fecal samples collected from the same
individuals at different time points and found that >95% of
virotypes were constant, but the abundance of bacterial popu-
lation changed over time [58]. Although the role of viral species
in human diseases is far from fully appreciated, inter-kingdom
interactions between bacteria, viruses, and eukaryotes in the
intestine have been shown to inﬂuence virulence of the organ-
isms and pathogenesis [59].
Altered diversity and abundance of the so-called ‘normal
ﬂora’ during disease development and progression were
unknown before the introduction of metagenomic sequencing,
since most of these organisms are non-culturable. 16S rRNA
sequencing has indicated a decrease in Bacteroides and
Firmicutes numbers in the colon and an increase in
Enterobacteriaceae, such as adherent-invasive E. coli and other
Proteobacteria in Crohn’s disease [60]. In contrast, obesity is
associated with fermenting bacterial species, such as
Bacteroides and Firmicutes, which can harvest energy from
complex polysaccharides [54]. Although the association of bac-
terial ﬂora with etiopathogenesis of disease is not fully estab-
lished, development of colitis and obesity following transfer
of disease-associated microbiota to gnotobiotic mice strongly
suggests disease association [61,62]. Animal models indeed
have emerged as invaluable tools to establish the underlying
mechanisms related to altered microﬂora in disease develop-
ment. Altered ﬂora may be the consequence of inﬂammation,
which may be demonstrated by reconstitution of germ-free
mice or piglets with the human disease ﬂora. Furthermore,
study of temporal changes in the microbiota by metagenomic
sequencing of genetically-predisposed individuals or their
ﬁrst-degree relatives may be helpful. Such information may
be therapeutically important, since an early intervention
appears to be critical to restore normal ﬂora [63].
Although various sequencing techniques have been used to
map the diversity of microbial communities that exist during
health and disease, microbiota-associated genes and geneproducts that may protect from or predispose to disease
remain largely unknown. Metagenomic sequencing data pro-
vide genetic composition of the whole microbiome, but give lit-
tle information about functioning of gene expression.
Functional metagenomics may be useful, but currently the
objective of sequencing is to identify functionally-important
non-abundant genes. Insights into the cellular and molecular
interactions between the host and the microbiota necessitate
integration of metagenomics with metatranscriptomics (gene
expression proﬁle), metaproteomics (protein mapping proﬁle),
and metabolomics (metabolic proﬁle) data. For example, com-
bination of metagenomics and metabolomics identiﬁed the role
of microbiota in dietary phospholipid metabolism, contribut-
ing to atherosclerosis [64]. Multiple omics platforms integrat-
ing metabolic changes in the host, including the metabolism
of drugs and environmental toxins, with microbiota diversity
have highlighted the necessity of personalized medicine. Gut
microbial enzymes for the metabolism of commonly-
prescribed drugs, such as acetaminophen and cholesterol-
lowering agent simvastatin, were identiﬁed [65,66]. In addition,
microbiota plays a critical role in the generation of more- (e.g.,
sulfasalazine) or less-active (e.g., digoxin) drug metabolites
[58]. Therapeutically active metabolite 5-aminosalicylate is
released from the prodrug sulfasalazine, while digoxin may
be converted to less active reduced derivatives by the action
of colonic microﬂora [34,67]. This implies that there may be
signiﬁcant inter-individual variability in the drug response
and/or adverse events. Similarly, toxin exposure may have very
different outcomes due to the variability in the microbiota
composition of the exposed individuals. Several neurotoxins
and carcinogenic metabolites may be generated by resident
microbes such as E. coli [68]. Identiﬁcation of individual
microbial species or the speciﬁc enzymes they produce with
the metabolites generated would make it possible to target
the microbiota for therapeutic purposes. This is best exempli-
ﬁed by the successful treatment of chemotherapy-associated
diarrhea following administration of CPT-11, a drug used in
colon cancers, by the use of bacterial b-glucuronidase enzyme
inhibitor [69].
Table 2 Highly-abundant bacterial species under different disease
conditions
Disease Name of prevalent bacteria Ref.
Symptomatic
atherosclerosis
Escherichia coli [42]
Eubacterium rectale
Eubacterium siraeum
Faecalibacterium prausnitzii
Ruminococcus bromii
Ruminococcus sp. 5_1_39BFAA
Type 2 diabetes Akkermansia muciniphila [49]
Bacteroides intestinalis
Bacteroides sp. 20_3
Clostridium bolteae
Clostridium ramosum
Clostridium sp. HGF2
Clostridium symbiosum
Colstridium hathewayi
Desulfovibrio sp. 3_1_syn3
Eggerthella lenta
Escherichia coli
Obesity/IBD/CD Acidimicrobidae ellin 7143 [50]
Actinobacterium GWS-BW-H99
Actinomyces oxydans
Bacillus licheniformis
Drinking water bacterium Y7
Gamma proteobacterium DD103
Nocardioides sp. NS/27
Novosphingobium sp. K39
Pseudomonas straminea
Sphingomonas sp. AO1
Colorectal cancer Acinetobacter johnsonii [47,51–53]
Anaerococcus murdochii
Bacteroides fragilis
Bacteroides vulgatus
Butyrate-producing bacterium A2-166
Dialister pneumosintes
Enterococcus faecalis
Fusobacterium nucleatum E9_12
Fusobacterium periodonticum
Gemella morbillorum
Lachnospira pectinoschiza
Parvimonas micra ATCC 33270
Peptostreptococcus stomatis
Shigella sonnei
Note: IBD, inﬂammatory bowel disease; CD, Crohn’s disease.
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generation therapeutics. On the one hand, it may be considered
as a repository of potential drugs or drug-like molecules, such
as antimicrobial peptide bacteriocin or thuricin CD, and
anti-inﬂammatory molecules like the cell wall polysaccharide
(Bacteroides fragilis) and peptidoglycan (Lactobacillus) [34].
Metagenomics coupled with bioinformatics may spearhead
the ‘bugs to drugs’ research. On the other hand, ‘disease micro-
biota’ may be targeted for treatment. Current therapies are
limited to non-speciﬁcally targeting the microbiota with probi-
otics, prebiotics, and synbiotics to restore the ‘healthy ﬂora’
[70–73]. Probiotics therapy has shown promise in the treatment
of acute diarrhea and prophylaxis against necrotizing entero-
colitis [74]. Although the exact mechanism of action remains
unknown, these organisms may render the host resistant to
colonization by pathogens through competing with them forthe intestinal niche, in addition to their bactericidal function,
thus creating an environment for the lost ﬂora to re-
establish. Fecal transplantation of the healthy ﬂora has been
successfully employed for the treatment of drug-resistant or
recurrent Clostridium difﬁcile-associated diarrhea [24].
However, the results are less-encouraging in obesity and
chronic diseases like diabetes mellitus, IBD, and IBS [53]. In
these conditions, early institution of therapy before an altered
ﬂora is established in the affected individuals or treatment of
the high-risk groups, such as ﬁrst-degree relatives of the
patients, may be more helpful. It is unlikely that a single pro-
biotic or a speciﬁc combination would be effective in all condi-
tions and subjects. Therefore, a more personalized treatment
may be required based on the microbiota composition to
ensure a predicted outcome.
A major bottleneck to the speciﬁcity of microbiota-targeted
therapies is our limited knowledge about the resident organ-
isms and their interactions with the host. Moreover,
microbe–microbe cross-talk may inﬂuence the disease out-
come. Naturally, members of the microbiota with known gen-
ome sequences or biochemical functions will be the initial
targets for drug or vaccine development. However, non-
speciﬁcity of the effects, which potentially results in removal
of beneﬁcial ﬂora and development of resistance, may be issues
that will require further attention. A systems biology approach
may be required with a therapeutic goal to restore the
biochemical, proteomic, and metagenomic proﬁles of an
individual.
Importance of microbial interaction network
Gut microbiota is an example of a complex ecological commu-
nity involving interactions with the host cells as well as among
hundreds of bacterial species. These interactions may be of ﬁve
different types including (i) mutualism, where both the partic-
ipants are beneﬁted; (ii) amensalism, where one organism is
inhibited or destroyed and the other is unaffected; (iii) com-
mensalism, where one partner gets the advantage without
any help or harm to the other; (iv) competition, where both
the participants harm each other; and (v) parasitism, where
one gets beneﬁted out of the other [8].
Establishing a model of the gut microbial interaction net-
work is a major challenge for the scientiﬁc community and lit-
tle progress has been made in this area. Predictions of
microbial associations may include a simple binary mode or
complex relationship, where more than two species are
involved in an absence–presence relationship (1 or 0 mode)
or abundance data (quantitative values obtained from OTU).
It is possible to predict the simple binary or pair-wise microbial
relationship using a similarity-based network inference, while
the complex microbial relationship can be predicted using
regression and a rule-based modeling approach. The
similarity-based network inferences are based on co-
occurrence and/or mutual exclusion pattern of two species
over different sampling conditions. Pair-wise relationship
scores are computed and further compared with the random
co-occurrence scores using a similar sampling approach.
Faust et al. recently built a gut microbiota network with co-
occurrence relationship using Spearman rank correlation
method. Here, 16S rRNA marker genes were used for compro-
mised gut in children with anti-islet cell autoimmunity [75].
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biota and their body niches. The dominant species at a speciﬁc
body site emerged as a ‘‘hub’’ in the network and was found to
act as the signature taxa, which was responsible for the compo-
sition of each microcommunity. Examples for hubs include
Bacteroides in the gut and Streptococcus in the oral cavity.
This microbial association is also reﬂected in their phyloge-
netic and functional relatedness. Especially, phylogenetically
related microbes have been found to co-occur at environmen-
tally similar body sites [75]. However, this type of approach
cannot be applied to complex, nonlinear, and evolving sys-
tems, where more than one dominant species are present at
any point of time and the abundance changes over time. In
such cases, the regression model and rule-based model are
used, where the abundance of one species is predicted from
combined abundances of the organisms in the system [76].
Generalized Lotka–Volterra (gLV) equations are used to study
these complex types of dynamic microbial community interac-
tions [77]. Few examples are present where gut microbiota is
used to develop diet-induced predictive models [63]. In this
model, a linear equation connects microbiota changes to given
concentrations of each of the four dietary ingredients (Casein,
Starch, Sucrose, and oil). There is still limited knowledge
about the gut microbial interactions and interactions between
the microbes and the host. In-depth investigation is required to
model these interactions in a better way and predict the out-
come of community-level microbial interactions after external
disturbance of the gut system due to diseases or the use of
drugs.
Whole genome sequencing of gut microbiota
16S rRNA-based sequencing of metagenomes is an established
approach for the identiﬁcation of known bacteria, based on
the reference sequences. However, most bacterial species of
the gut microbiota are novel, for which no reference sequence
is available. Moreover, 16S sequencing does not provide any
functional input about the community, since the sequence is
not strain-speciﬁc. Gene contents may differ between bacterial
strains with identical 16S rRNA gene sequence and underlie
their functional difference related to genes responsible for tox-
icity and pathogenesis [78]. WGS of the microbiota (e.g.,
Human Microbiome Project Consortium, 2012) is preferred
over 16S rRNA-based analysis to elucidate taxonomic classiﬁ-
cation and bacterial diversity within members of the microbial
community. WGS is also useful for a detailed understanding of
the functional potential of the microbiome. For example, fecal
metagenomic data obtained from WGS of 124 unrelated indi-
viduals along with six monozygotic twin pairs and their moth-
ers were analyzed by the construction of community level
metabolic networks of the microbiome. It was observed that
gene-level and network-level topological differences are
strongly associated with obesity and IBD [79]. WGS of 252
fecal metagenomic samples in another study showed huge vari-
ations at the metagenomic level, in which authors identiﬁed
107,991 short insertions/deletions, 10.3 million single nucleo-
tide polymorphisms (SNPs) and 1051 structural variants. In
addition, they found that despite considerable changes in the
composition of the gut microbiota, the individual speciﬁc
SNP variation pattern showed a temporal stability. This
further suggests that every individual carries a uniquemetagenome, which can be exploited further for personalized
medicine or dietary modiﬁcations [80]. Many 16S rRNA-
based studies have reported a connection between the gut
microbiota and health [24,39,59]. A detailed WGS based anal-
ysis of the gut metagenome may help to better understand the
disease pathogenesis and identify new targets for therapy,
because it may reveal minor genomic variations within species
that cause altered phenotypes, leading to pathogenesis. For
instance, WGS studies with Citrobacter spp. showed that geno-
mic variations within species altered their phenotype and envi-
ronmental adaptation [81].
Currently, Illumina shotgun sequencing of stool samples is
widely used for WGS studies of the gut microbiome. Since the
gut contains diverse microbial species, a deep sequencing
(20 · coverage) is required to study individual communities
with low abundance [81]. However, analyzing the large volume
of WGS data (short reads) is very challenging, as there may be
from hundreds to thousands of bacterial species present with
different abundances, especially as there is no taxonomic iden-
tiﬁcation available for most of the species.
Tools/web-servers related to gut microbiota studies
To overcome the challenges in metagenomic data analysis, sev-
eral standalone software, web servers, and R packages have
been developed and are available in the public domain
(Table 3). Here, we focus on the popular software, which can
be used in studying gut microbiota. There are many standalone
tools, which may be used for the analysis of 16S rRNA marker
gene sequencing data and the WGS data. Quantitative Insights
Into Microbial Ecology (QIIME), investigates microbial diver-
sity using 16S rRNAs data. It provides the users with taxon-
omy assignments to phylogenetic analysis along with
demultiplexing and quality ﬁltering of the raw reads generated
from Illumina or other platforms. But the installation of
QIIME needs some expertise in Linux and Windows systems,
and it lacks parallel processing at the OTU picking step [82].
mothur is a software package with several functions, including
identiﬁcation of OTUs and description of alpha (within a
speciﬁc sample) and beta (between different samples) diversity
between different samples [83]. RAMMCAP is a GUI-based
tool, which performs metagenomic sequence clustering and
analysis and can process a huge number of sequences in a very
short time compared to other tools and software. RAMMCAP
also includes protein family annotation tool and a novel GUI-
based metagenome comparison method based on statistical
analysis [84]. For WGS-based sequencing data analysis
(mainly for taxonomy binning), several approaches are avail-
able, which integrates Basic Local Alignment Search Tool
(BLAST) for species identiﬁcation. The tool MEtaGenome
ANalyzer (MEGAN) uses BLAST search against a reference
sequence database like non-redundant sequence database from
NCBI NR database and provides results in a graphical user
interface (GUI). It allows large datasets to be dissected with-
out further assembly or the targeting of speciﬁc 16S rRNA
marker gene. It can also compare different datasets based on
statistical analysis and provides graphical output [85].
Metagenomic Phylogenetic Analysis (MetaPhlAn) is another
tool that provides faster taxonomic assignments by removing
redundant sequences [86]. Short reads need to be assembled
into contigs, which are similar in length to a gene, so that they
Table 3 Tools/webservers related to gut microbiota studies
Name Platform Website Main features Ref.
QIIME Stand alone http://qiime.sourceforge.net/ Network analysis, histograms of within- or between-sample
diversity
[82]
mothur Stand alone http://www.mothur.org/ Fast processing of large sequence data [83]
RAMMCAP Stand alone http://weizhonglab.ucsd.edu/rammcap/cgibin/rammcap.cgi Ultra fast sequence clustering and protein family annotation [84]
MEGAN Stand alone http://www-ab.informatik.unituebingen.de/software/megan/ Laptop analysis of large metagenomic shotgun sequencing data
sets
[85]
MetaPhlAn Stand alone http://huttenhower.sph.harvard.edu/metaphlan Faster proﬁling of the composition of microbial communities using
unique clade-speciﬁc marker genes
[86]
MetaVelvet Stand alone http://metavelvet.dna.bio.keio.ac.jp/ High quality metagenomic assembler [87]
SOAPdenovo2 Stand alone http://soap.genomics.org.cn/soapdenovo.html Metagenomic assembler, speciﬁcally for Illumina GA short reads [88]
MOCAT Stand alone http://vmlux.embl.de/~kultima/MOCAT/ Generate taxonomic proﬁles and assemble metagenomes [89]
SmashCommunity Stand alone http://www.bork.embl.de/software/smash/ Performs assembly and gene prediction mainly for data from
Sanger and 454 sequencing technologies
[90]
HUMAnN Stand alone http://huttenhower.sph.harvard.edu/humann Analysis of metagenomic shotgun data from the Human
Microbiome Project
[91]
FANTOM Stand alone http://www.sysbio.se/Fantom/ Comparative analysis of metagenomics abundance data integrated
with databases like KEGG Orthology, COG, PFAM and
TIGRFAM, etc.
[92]
MetaCV Stand alone http://metacv.sourceforge.net/ Classiﬁcation short metagenomic reads (75–100 bp) into speciﬁc
taxonomic
[94]
Phymm Stand alone http://www.cbcb.umd.edu/software/phymm/ Phylogenetic classiﬁcation of metagenomic short reads using
interpolated Markov models
[97]
PhyloPythiaS Web server http://binning.bioinf.mpiinf.mpg.de/ Fast and accurate sequence composition-based classiﬁer that
utilizes the hierarchical relationships between clades
[96]
TETRA Web server http://www.megx.net/tetra Correlation of tetranucleotide usage patterns in DNA [93]
METAREP Web server http://www.jcvi.org/metarep/ Flexible comparative metagenomics framework [98]
CD-HIT Web server http://weizhonglab.ucsd.edu/cd-hit/ Identity-based clustering of sequences [99]
METAGENassist Web server http://www.metagenassist.ca/ Performs comprehensive multivariate statistical analyses on the
data from diﬀerent host and environment sites
[100]
CoMet Web server http://comet.gobics.de/ ORF ﬁnding and subsequent Pfam domain assignment to protein
sequences
[101]
WebCARMA Web server http://webcarma.cebitec.unibielefeld.de/ Unassembled reads as short as 35 bp can be used for the taxonomic
classiﬁcation with less false positive prediction
[102]
MG-RAST Web server https://metagenomics.anl.gov/ High-throughput pipeline for functional metagenomic analysis [103]
CAMERA Web server https://portal.camera.calit2.net/gridsphere/gridsphere Provides list of workﬂows for WGS data analysis [104]
WebMGA Web server http://weizhonglilab.org/metagenomic-analysis/ Implemented to run in parallel on local computer cluster [105]
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Mandal RS et al / Metagenomic Analysis of Gut Microbiota 155may be annotated for function inference. Such assembly can be
performed using tools such as MetaVelvet [87] and Short
Oligonucleotide Analysis Package (SOAPdenovo2) [88].
Moreover, simultaneous assembly and annotation are also
possible with some software packages, such as MOCAT, which
assembles metagenomic short reads into contigs along with
quality control and performs gene prediction from contigs
[89]. For functional analysis of the metagenomic reads, pre-
dicted genes from the assembled contigs or raw sequence reads
with long read length may be used. To annotate functions to
the sequences or genes, Kyoto Encyclopedia of Genes and
Genomes (KEGG) organizes genes into KEGG enzymes,
pathways, and orthologs appropriate for the elucidation
of metabolic potential of the community. Certain pipelines,
such as SmashCommunity [90], Microbiome Project Uniﬁed
Metabolic Analysis Network (HUMAnN) [91], and
Functional Annotation and Taxonomic Analysis of
Metagenomes (FANTOM) [92], which are easy-to-use GUIs
for metagenomic data analysis, are also available to automate
the process of assembly and annotation.
Most of the aforementioned tools use known 16S rRNA
reference sequence databases like RDP (http://rdp.cme.msu.
edu/) and Greengenes (http://greengenes.lbl.gov) to assign tax-
onomy information to the unknown sequence. Nonetheless,
some WGS-based unsupervised tools, such as TETRA [93],
MetaCV [94], and PhyloPythia [95], are also available. They
use different sequence features for taxonomy binning.
TETRA is a DNA-based ﬁngerprinting technique for genomic
fragment correlation based on tetranucleotide usage pattern,
while MetaCV is an algorithm based on composition and
phylogeny to classify short metagenomic reads (75–100 bp)
into speciﬁc taxonomic and functional groups. Similarly,
PhyloPythiaS web server [96] is also is a fast and accurate clas-
siﬁer based on sequence composition utilizing the hierarchical
relationships between clades. Among these composition-based
classiﬁcation methods, Phymm [97] is another classiﬁer for
metagenomic data that has been trained on 539 complete,
curated bacterial and archaeal genomes, and can accurately
classify reads as short as 100 bp. Along with TETRA and
PhyloPythiaS web servers, several other online web-servers
are also available for metagenomic analysis. METAREP is a
web 2.0 application, which provides graphical summaries for
top taxonomic and functional classiﬁcations. It also provides
Gene Ontology (GO), NCBI Taxonomy and KEGG
Pathway Browser-based comparison of multiple datasets at
various functional and taxonomic levels [98]. Another online
tool, CD-HIT, can be used in identiﬁcation of non-
redundant sequences and gene-families by clustering raw reads
[99]. METAGENassist, a web server for comparative metage-
nomics, can be used for comprehensive multivariate statistical
analyses on the bacterial census data from different environ-
ment sites or different biological hosts selected by the users
[100]; CoMet, another web-based comparative metagenomics
platform is used for the analysis of metagenomic short read
data resulting from WGS-based studies. It integrates ORF ﬁn-
der, Pfam domain detection software and statistical analysis
tools to a user-friendly web interface for functional compar-
ison of metagenomic data from multiple samples [101].
WebCARMA is a web application for taxonomic classiﬁcation
of ultra-short reads as 35 bp [102]. MG-RAST (the
Metagenomics RAST) server is an automated platform for
the analysis of microbial metagenomes to get the quantitativeinsights of the microbial populations . Modularity of MG-
RAST allows new analysis steps or comparative data to be
added during the analysis according to the user’s need. It
enables the user to annotate multiple metagenomes at a time
and also to compare the metabolic data [103].
CAMERA [104] and WebMGA [105] are also frequently
used web servers for metagenomic data analysis. CAMERA
offers a list of workﬂows, but many useful tools are missing,
such as Filter-HUMAN, RDP-binning, FR-HIT-binning,
and CD-HIT-OTU, which are otherwise available with
WebMGA. Filter-HUMAN is a tool for ﬁltering human
sequences from human microbiome samples. RDP-binning
uses the binning tool from Ribonsomal Database Project
(RDP) to classify rRNA sequences. FR-HIT-binning ﬁrst
aligns the query metagenomic reads to NCBI’s Refseq data-
base and then classiﬁes reads to the speciﬁc taxon, which is
the lowest common ancestor (LCA) of the hits. CD-HIT-
OTU is a clustering program able to process millions of
rRNAs in a few minutes. Moreover, both MG-RAST and
CAMERA require user registration and login, so it is difﬁcult
to access their web servers using scripts. However, WebMGA
has resolved these issues and allows a fast, easy and ﬂexible
solution for metagenomic data analysis. The user can perform
data analysis through customized annotation pipeline and it
does not require any login information. In addition, metaphor
package is also available for users having expertise in R statis-
tical language (http://CRAN.R-project.org/package=meta-
for). Although these programs are widely used for
metagenomic data analysis, there is still a bottleneck to iden-
tify novel bacteria, as a majority of them are unknown.Conclusion and future prospects
We have reached a level of saturation regarding 16S rRNA
sequence catalogs of gut microbiota from the Western popula-
tion. This is exempliﬁed by the fact that we are fairly close to
identifying all gene families encoded by the human gut micro-
biota of the Western population. It has been observed that the
bacterial phylogeny obtained from the gut microbial DNA
sequencing of 124 individuals is not much different from that
of the ﬁrst 70 individuals [55]. While the above ﬁndings need
to be extended to diverse phenotypes (populations, diseases,
age, etc.), more efforts should be directed to compile reference
genomes, which will require WGS, and perhaps, culturing indi-
vidual organisms. In addition, there are multiple ecosystems
along the length of the gut, which remain unexplored in terms
of metagenomic diversity. An increasing number of studies in
the future will be directed toward understanding the functions
of the microbiome and RNA-seq may play a critical role.
However, preparing high quality representative RNAs for
sequencing to generate metatranscriptome is a challenge.
As opposed to the sequencing data, functional annotations
of the genes are grossly incomplete due to the unavailability of
suitable computational tools and we have only limited knowl-
edge about the metabolic functions of the microbiota. Germ-
free animals are valuable tools for functional assessment of
the microbiota and their association with diseases, but high
variability between facilities is a major problem for data inter-
pretation. Microbiota has great potential for the identiﬁcation
of genetic biomarkers of disease, but proper statistical analysis
is extremely difﬁcult.
156 Genomics Proteomics Bioinformatics 13 (2015) 148–158Finally, the association of gut microbiota with human dis-
eases has obliterated the boundary between infectious and
non-infectious diseases. While the manipulation of microbiota
has immense therapeutic potential, techniques need to be
developed to manipulate individual bacteria within a commu-
nity and for targeted therapy, such as designer probiotics.
There is an urgent need for novel approaches toward the con-
struction of gut ecosystem-wide association networks to
develop global models of gut ecosystem dynamics. Such mod-
els may then, predict the outcome of perturbation effects in the
gut and eventually aid in therapeutic intervention.
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